Overview of Solesta

Property	Description
Active Ingredients	Dextranomer, Sodium Hyaluronate
Form	Sterile Injectable Gel (Implant)
Pharmacological Class	Tissue Bulking Agent
General Purpose	Structural support and tissue augmentation
Origin	Synthetic/Derived (Non-animal polysaccharides)

What Type of Medical Product is Solesta?

Solesta is a sterile injectable gel classified as a specialized Tissue Bulking Agent, clinically recognized for its role in structural tissue augmentation. It is distinctly not a systemic medication, but functions as a physical implant delivered via ano-rectal injection into the deep submucosal layer, holding a Class III medical device classification. This structural filler represents a minimally invasive treatment alternative, particularly for adults who have not responded adequately to conservative therapies. It is used as a local, volume-enhancing treatment option for related conditions.

Composition: Dextranomer and Sodium Hyaluronate

Solesta is a specific combination product comprised of two biocompatible polymeric substances: Dextranomer microspheres and stabilized Sodium Hyaluronate. Both components are biosynthesized polysaccharides of non-animal origin. The Dextranomer acts as the primary, long-lasting bulking material, while the Sodium Hyaluronate functions as a viscous carrier, enabling the precise delivery of the implant into the soft tissue. The Dextranomer microspheres are designed to be stable, providing lasting, sustained physical support, essential for the product's long-term effect.

Solesta's General Purpose as a Structural Filler

The general purpose of Solesta is to enhance tissue support by mechanically increasing the volume and thickness of the soft tissue walls. This physical intervention achieves tissue augmentation, which is the core mechanism supported by pharmacological data. By acting as a structural filler, the implant provides a stable framework, leading to the gradual creation of native collagen deposition and reinforced tissue structure. The resulting benefit is directly related to this durable, physical enhancement, supporting the body's passive ability to maintain continence.

What side effects are possible with Solesta?

Possible Side Effects and Safety Information

The official safety information for Solesta is defined by specific conditions that prohibit its use, necessary procedural warnings, and documented adverse reactions classified by frequency and body system.

Absolute Contraindications and Warnings

Solesta is strictly contraindicated in specific patient populations due to increased risk. These absolute restrictions include patients with:

Active inflammatory bowel disease (IBD).
Immunodeficiency disorders or ongoing immunosuppressive therapy.
Previous radiation treatment to the pelvic area.
Significant mucosal or full thickness rectal prolapse.
Active anorectal conditions, such as abscesses, fissures, sepsis, bleeding, proctitis, or other infections.
Anorectal atresia, tumors, stenosis, or malformation.
Allergy to hyaluronic acid-based products.

Regulatory warnings explicitly state that the product must not be injected intravascularly, as this carries a risk of vascular occlusion.

Adverse Reactions by Frequency and System

The majority of adverse events reported in clinical studies were mild to moderate in severity and typically resolved quickly. They are most commonly related to the injection site and the gastrointestinal system.

Classification	Examples of Documented Reactions
Most Common (Incidence > 4%)	Proctalgia (pain in the anus or rectum), anorectal or injection site hemorrhage (bleeding), pyrexia (fever), injection site pain, diarrhea, and anorectal discomfort.
Common to Uncommon	Rectal discharge, constipation, lower abdominal pain, defecation urgency, anal pruritus (itching), anal prolapse, and rectal abscess.

Serious Adverse Reactions

Serious adverse events reported in regulatory documentation include cases of rectal/anorectal abscess and instances of pyrexia. The adverse event profile suggests that the highest incidence of treatment-related events occurs within the first 48 hours following the injection procedure.

This structure ensures that patients and providers are informed of conditions that strictly prohibit use, key procedural risks, and the most frequently expected localized side effects.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents for Solesta (Dextranomer, Sodium Hyaluronate injectable gel) indicate that a conventional pharmacological overdose is unlikely to occur. This is consistent with its classification as a non-systemic, local implant that is administered only by a qualified healthcare professional in a controlled clinical setting.

Documented Critical Manifestations

The regulatory labeling defines the risk profile based on severe complications from the administration procedure. The most serious outcome explicitly warned against is vascular occlusion resulting from the inadvertent injection of the gel into a blood vessel. The official information also notes that severe local events, such as heavy rectal bleeding (hemorrhage) or the development of a significant local infection, constitute critical events.

When Immediate Medical Help Is Required

Government guidance mandates that immediate medical attention must be sought upon the observation of specific, severe manifestations. These triggers include, but are not limited to:

The onset of severe or heavy rectal bleeding.
Signs of a developing severe local infection, such as new fever, severe rectal pain, swelling, or localized drainage (pus).
The appearance of bulging tissue from the rectum.

No specific antidote is documented in the official labeling. Treatment for any severe complication is supportive and symptomatic, with prophylactic or therapeutic antibiotic medication listed as a measure to manage or prevent infection.

Therapeutic Uses of Solesta

What Solesta Treats: Main Uses and Benefits

Solesta is a medical product used to help manage Fecal Incontinence (FI) in adults who may experience symptoms that create noticeable physiological strain and have not achieved symptom control with conservative, non-surgical therapies. The use of this product is relevant for patients 18 years and older who have failed conservative symptomatic management, such as changes to diet or fiber therapy. This therapeutic area includes conditions presenting with acute episodes.

The primary therapeutic domain involves managing symptom clusters related to the involuntary loss of bowel control and unpredictable anal leakage. Solesta is applied across domains where additional symptomatic support is needed, primarily addressing persistent mild-to-moderate symptoms of Fecal Incontinence. The primary benefit contributes to easing the overall symptom load and is relevant for managing symptoms that interfere with daily comfort, which generally helps maintain a sense of stability when symptoms are more noticeable.

This treatment is considered relevant for patients with recurrent or chronic episodes of FI. It is commonly used when symptoms intensify and supportive relief is needed. The symptomatic support contributes to improved coping ability and reduced embarrassment, supporting patients during difficult episodes by easing distress and ultimately assisting with maintaining functional stability.

Quick Fact: Relief for Involuntary Bowel Leakage

Solesta is commonly used to help with symptomatic relief in conditions involving involuntary anal discharge and the resulting loss of bowel control, providing support that helps ease the overall symptom burden when conservative measures have failed.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Solesta

Category	Official Regulatory Statement
Populations for whom use is allowed	Adults 18 years and older who have failed conservative therapy (e.g., diet, fiber therapy).
Populations for whom use is contraindicated	Patients with active inflammatory bowel disease, immunodeficiency disorders, previous pelvic radiation, significant rectal prolapse, rectocele, rectal varices, or known allergy to hyaluronic acid products.
Age-related eligibility rules	Minimum Age: 18 years. Pediatric Use (under 18): Safety and effectiveness have not been studied.
Condition-specific eligibility rules	Contraindicated in patients with active anorectal conditions (e.g., abscess, fissures, sepsis, bleeding, tumors, or malformation).
Pregnancy and lactation eligibility status	Not Established: Safety and effectiveness have not been studied in pregnant or breastfeeding women.
Eligibility-related restrictions	Use requires caution in patients with bleeding diathesis or those using anticoagulant agents. A modified injection procedure is required for men with an enlarged prostate.

Official Eligibility Structure

Official regulatory documents define Solesta's population eligibility based on mandatory age and prior treatment requirements, restricting use to adults who have failed conservative measures. Use is absolutely prohibited for patients presenting with local structural anomalies, active infection, or systemic immune issues. The regulatory status for pediatric, pregnant, and breastfeeding populations is classified as not established due to a lack of specific safety and effectiveness data.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Solesta (Dextranomer/Sodium Hyaluronate injectable gel) is officially classified as a local, non-systemic tissue bulking agent. As a result of this classification, the regulatory profile confirms the absence of documented systemic pharmacokinetic interactions, including those mediated by cytochrome P450 enzymes or drug transporters.

The interaction constraints are primarily based on procedural risks and local administration restrictions.

Procedural and Local Pharmacodynamic Interactions

Co-administration of anticoagulant agents or antiplatelet agents is associated with an increased procedural risk of bleeding at the injection sites. This is a pharmacodynamic constraint related to the injection procedure itself. Similarly, avoidance of Nonsteroidal Anti-inflammatory Drugs (NSAIDs) is advised immediately following treatment to minimize this risk.

Mandatory Interaction-Related Restrictions

Regulatory labeling establishes explicit restrictions on co-use and timing to protect the injection site:

Contraindicated Combinations: The co-presence of any existing implant other than Solesta in the anorectal region is formally prohibited, and the product must never be mixed with other substances during administration.
Timing Separation: The use of anti-diarrhea medicine is restricted for at least one week after treatment. The insertion of rectal objects (e.g., suppositories, enemas, thermometers) must be avoided for at least one month following the injection.

Mechanism of Action

The mechanism of Solesta is structural and mechanical, distinct from pharmacological approaches. It relies on the localized action of its two components to physically augment tissue volume and promote long-term stabilization, resulting in an alteration of the local tissue's biomechanical properties.

Physical Augmentation and Local Space Occupation

This mechanism begins with the immediate action where the non-absorbable Dextranomer microspheres, delivered by the viscous Sodium Hyaluronate carrier, mechanically displace the deep submucosal tissue. This physical space-occupying effect instantly increases the local tissue volume and density, establishing the initial passive structural resistance.

Biologically Induced Structural Stabilization

This second domain involves a localized biological process where the inert Dextranomer matrix triggers the recruitment of fibroblasts within the surrounding tissue. This cellular response leads to neocollagenesis—the deposition of new, native collagen—which encapsulates the microspheres, converting the initial volume into a stable, integrated tissue structure.

Component Synergy for Persistence

The mechanism relies on the distinct, complementary roles of its components: Sodium Hyaluronate provides the necessary viscosity for controlled delivery and precise initial placement, while Dextranomer functions as the non-degradable permanent physical scaffold and template, promoting sustained augmentation and structural presence over time.

Dosage and Administration Information

How to Use Solesta

Solesta is administered as a single-session, local implant and is not a conventional systemic medication. Its usage is strictly governed by the product’s official labeling, which outlines the required route, dose, and administration conditions. This procedure is performed by a specialized physician and is typically done in an outpatient setting.

Official Administration and Dosage

Parameter	Official Instruction
Route of Administration	Submucosal injection into the deep submucosal layer of the anal canal.
Dosing Regimen	A total volume of 4 mL is administered. This consists of four (4) separate 1 mL injections in a single treatment session.
Frequency	An initial single treatment session is standard. A repeated procedure may be required if necessary.
Age Requirement	Indicated for patients 18 years and older.

Procedural and Preparation Requirements

Proper use of the product requires adherence to specific pre-procedure and procedural steps:

Preparation: The patient must complete adequate bowel preparation immediately prior to the procedure. The administration of prophylactic antibiotics is also recommended.
Technique: The injection must be performed slowly and by a physician experienced and trained in the Solesta procedure.
Special Constraint: In male patients, injection in the midline of the anterior rectal wall should be avoided if an enlarged prostate is present.

These official instructions establish the standardized approach to delivering the structural implant and define the necessary conditions for its correct application.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Solesta

Evidence for use in Fecal Incontinence (FI)

Solesta was studied for Fecal Incontinence (FI) in adults who had not adequately responded to conservative therapies, such as dietary adjustments or fiber supplements. The core research includes a randomized, sham-controlled, double-blind trial. This design is a standard study design, involving comparison against an inactive, non-therapeutic procedure (the sham), where neither the participants nor the staff know who received which. This design was used in research exploring how symptoms change over time and helps researchers observe how patients report their experiences.

In these studies, research examined outcomes related to physical discomfort and daily functioning. The main findings describe patterns observed in the studies, including measurements of changes in the frequency of FI episodes among participants. However, the pivotal trial design was associated with a reported measurement of improvement in a proportion of the group that received the sham treatment as well. This evidence contributes to the broader evidence landscape regarding this treatment for FI.

Study Outcomes and Measures

Clinical research was evaluated in trials assessing short-term or episodic symptom patterns and focused on two main axes: the objective change in physical symptoms and the patient’s perceived quality of life. Beyond episode frequency, research explored patient-reported outcomes describing perceived discomfort and overall daily functioning. This involved using validated surveys like the Fecal Incontinence Quality of Life (FIQOL) scale.

In the initial, double-blind phase of the research, the findings were mixed regarding how much the scores for patient-reported quality of life changed when directly compared to the sham-treated group at the six-month mark. While changes were observed in some studies, the study results reflect the specific conditions under which they were conducted.

Long-Term Research and Follow-up

To track outcomes over time, follow-up durations were observed in studies over defined time intervals. The initial primary efficacy endpoints were set at 6 and 12 months. This research provides insight into short-term changes but not necessarily the response over many years. Available data extends up to 36 months (three years). However, the long-term effects are not fully established by randomized, sham-controlled data beyond the first year. The non-comparative nature of these extended follow-up studies means that there is limited information for long-term outcomes when directly compared against a non-treated group.

Frequently Asked Questions (FAQ)

Common questions about Solesta (FAQ)

Q: How quickly should someone expect to notice the effects of Solesta?

Clinical data indicates that the treatment may begin working soon after the procedure.

Studies observed that optimal results were generally noted at 3 months for many of the patients who received the treatment.

Q: How long does the intended effect of Solesta typically last?

Studies have examined the durability of Solesta, and the data available extends up to 36 months (three years) following the last injection.

The studies observed that the reported reduction in symptoms persisted at the 36-month follow-up.

Q: Is Solesta a permanent or temporary treatment option?

Solesta is designed as a permanent injectable implant because the main Dextranomer material is not absorbed by the body.

However, regulatory information states that a repeated procedure may be required in some cases to maintain a satisfactory level of improvement over time.

Q: Is it possible for the Solesta material to be absorbed or break down over time?

The product is designed to be a permanent injectable implant.

Regulatory documents confirm that the Dextranomer component, which forms the main physical scaffold, is officially described as non-degradable.

Q: What is the success rate described in clinical studies for Solesta?

Clinical studies measure success not by an overall single rate, but by specific endpoints, such as the "Responder50" proportion.

This proportion is defined as the percentage of patients achieving a 50% or greater reduction in episodes of fecal incontinence. This specific rate was an endpoint examined at different time points, such as 6 and 12 months.

Q: What happens if Solesta does not provide the expected result for someone?

Official product information notes that a repeated Solesta injection procedure may be required if the initial treatment does not yield the expected level of improvement.

If necessary, a repeat treatment may be administered no less than four weeks after the initial procedure.

Q: Will I be able to feel the Solesta material inside my body after the procedure?

Regulatory warnings state that the Solesta material might be detected during future medical examinations, such as x-rays.

Official documents do not include explicit information on a patient’s ability to sense the implant material inside the body.

Q: Are there any specific dietary restrictions needed with Solesta?

Post-procedure care instructions indicate that patients can generally resume a regular diet as tolerated shortly after the injection.

Specific temporary restrictions are noted for alcohol and antidiarrheal medicine immediately following the procedure.

Q: What long-term data exists regarding the safety of Solesta?

Clinical study reports examined the adverse event profile of Solesta for a duration extending up to 36 months post-injection.

Evidence indicates that 96% of the adverse events reported over 18 months were categorized as mild or moderate in severity.

Q: Are the side effects of Solesta generally reversible?

Study results indicate that the majority of adverse events reported were mild to moderate in severity and resolved quickly.

In clinical studies, 96% of events required no intervention or required simple noninvasive interventions.

Q: Does Solesta interact with moderate alcohol consumption?

Post-procedure care instructions include a restriction to avoid alcohol, including beer and wine, for 24 hours following the procedure.

This precaution is also advised while taking any prescribed narcotic pain medicine.

Q: What patient groups were included in the main Solesta research trials?

The main research trials enrolled a specific group of patients, including those aged 18 to 75 years.

All enrolled participants had previously failed conservative therapy and had a documented minimum of four or more fecal incontinence episodes in the two weeks prior to the study.

Q: What is the general outline of the process for receiving the Solesta treatment?

The treatment is administered in an outpatient setting and does not require general anesthesia.

The process involves specific preparation steps immediately prior to the injection, including adequate bowel preparation and the administration of prophylactic antibiotics.

Q: Can Solesta affect a person's ability to return to daily activities right away?

Post-treatment instructions indicate that limited physical activity may be resumed immediately after the procedure.

Instructions also note the need to avoid strenuous physical activity and sexual intercourse for the first week (7 days).

Q: What is the rate of complications reported in official documents for Solesta?

Regulatory documents report that the highest incidence of treatment-related adverse events occurs within the first 48 hours following the injection.

Furthermore, evidence indicates that only 1.3% of treatment-related adverse events in the clinical study were deemed serious.

Q: Does the therapeutic effect of Solesta diminish completely over time?

Long-term study results indicate that the reduction in fecal incontinence episodes remained at 52.2% at 36 months after treatment.

This evidence suggests a continued therapeutic effect over the studied three-year period.

Q: Is Solesta approved for use in countries outside of the US?

Solesta has been commercially distributed and studied in countries outside the US.

Official information confirms that it has been used in parts of Europe, including the UK, France, Sweden, and Germany.

Q: What is the required follow-up care or monitoring after getting Solesta?

Post-treatment instructions include guidance on informing other healthcare providers about the implant, as it might be detectable during examinations.

The guidance also notes when to seek immediate medical attention for symptoms, such as fever, difficulty emptying bowels, or excessive bleeding after the procedure.

Q: What is the clinical evidence regarding the long-term effectiveness of Solesta?

Follow-up data for the treatment extended up to 36 months (three years) in studies.

However, regulatory documents note that long-term effects are not fully established by randomized, sham-controlled data beyond the first year.

How should Solesta be stored and disposed of?

How to Store and Dispose of Solesta?

The storage and disposal protocols for Solesta Injectable Gel are strictly defined by regulatory requirements to maintain product integrity and ensure proper handling of medical waste.

Official Storage Requirements

Condition	Requirement
Temperature	Store at a temperature up to 25°C (77°F).
Protection	The product must be protected from sunlight and must not be exposed to freezing, as this can damage the device.
Stability	Solesta is supplied sterile and is for single use only. It must not be re-sterilized or mixed with any other product.

Disposal Instructions

Used Solesta syringes and needles must be handled as potential biohazards. Disposal of the product should be carried out in accordance with accepted medical practice, adhering to all applicable local, state, and federal regulatory requirements for medical waste.

Solesta